reMYND appoints Dr. Lode Debrabandere as Chief Business Officer

Written by: Editor
Published on: 18 Mar 2021

Leuven Belgium, 18 March 2021: reMYND NV, a clinical stage company developing innovative treatments for Alzheimer’s, diabetes and other diseases caused by cellular dysfunction, has appointed Dr. Lode Debrabandere as Chief Business Officer. Based on the East Coast of the Unites States, Dr. Debrabandere will be responsible for reMYND’s business development activities and global strategy and will lead the expansion of the Company’s network internationally.

Dr. Debrabandere joins reMYND with over 25 years of experience in senior positions across the biotechnology and pharmaceutical sectors. He spent ten years at Osiris Therapeutics, first as Vice President and General Manager of the Therapeutics Business Unit, where he was responsible for the development of Prochymal® (remestemcel-L), the world's first approved stem cell drug for graft versus host disease. In 2012, he was promoted to Chief Operating Officer before becoming President and Chief Executive Officer in 2013.

Previously, Dr. Debrabandere served as Vice President of Global Marketing at Bristol Myers Squibb where he led the Neuroscience Business Unit and was the Global Brand Leader for Abilify™. Lode has also served as Chief Executive Officer of Aziyo Biologics and founded 3RBiomed and Amynas. He began his career in Clinical Operations and Marketing at UCB, based in Belgium.

Dr. Debrabandere holds a Pharm.D in Pharmaceutical Sciences, a Ph.D in Toxicology and an MBA from the University of Leuven.

Dr. Lode Debrabandere, Chief Business Officer of reMYND commented: “I am thrilled to join reMYND and implement our international growth strategy. reMYND has the leadership team, advanced pipeline and strategic determination to bring first-in-class therapeutics to patients suffering from debilitating diseases, like Alzheimer’s, Diabetes, Huntington’s and ALS.”

Koen De Witte, Managing Director of reMYND commented: “Lode’s rich and varied experience as COO and CEO of various global biotech & pharmaceutical companies will be invaluable to realising reMYND’s growth well beyond business development and stepping up our international network.”